Premium
Prognostic irrelevance of HLA‐G in B‐cell chronic lymphocytic leukemia
Author(s) -
PEREZCHACON G.,
ROSADO S.,
REBOLLEDA N.,
LOSADAFERNANDEZ I.,
VARGAS J. A.,
MORADO M.,
JORDA J.,
PEREZACIEGO P.
Publication year - 2009
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/j.1751-553x.2008.01030.x
Subject(s) - chronic lymphocytic leukemia , immunology , flow cytometry , lymphoproliferative disorders , human leukocyte antigen , leukemia , b cell , antigen , immune system , medicine , cancer research , antibody , lymphoma
Summary In the last few years, it has been suggested that the involvement of human leukocyte antigen‐G (HLA‐G) in several tumoral processes and its likely participation as a factor of immune tolerance in malignant cells. Recently, positive HLA‐G surface expression has been associated with a poor prognosis in a small group of patients with B‐cell chronic lymphocytic leukemia (B‐CLL), a lymphoproliferative disorder characterized by a heterogeneous clinical course. In the present work, 169 patients suffering from B‐CLL were analyzed for the expression of HLA‐G by flow cytometry in order to verify its prognostic value in a larger cohort. We observed a low expression of this molecule on leukemic B cells and no significant relation to clinical data or progression‐free survival time, indicating that this molecule is not as good immunologic prognostic marker for B‐CLL as suggested.